Accelerated aging — when someone’s biological age is greater than their chronological age — could increase the risk of cancer tumors. That’s according to new research presented this week at the ...

High-school courses that let students pursue advanced study in mathematics and science should be more in-depth, and should also be made more widely available to poor and minority students, a report ...

The U.S. Food and Drug Administration's accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients' lives?

Less than half of the cancer therapies that were granted accelerated approval by the FDA between 2013 and 2017 showed a clinical benefit in a confirmatory trial within the next five years. That is the ...

New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that one's biological age, which can be higher than his or her chronological age – ...

A PERSON'S biological age could predict their risk of one of the most common cancers in the UK, according to a new study. Having a higher biological age than chronological age is a concept known as ...

(WTHR) — A large study of brain scans has yielded surprising results for researchers: cannabis use is one of the leading factors of accelerated brain aging. The study, published by the Journal of ...

Shortcuts aren’t common in medicine, but BrainsWay may have found an effective one for treating major depressive disorder. The company’s Deep Transcranial Magnetic Stimulation (Deep TMS) technology ...

Comparative clinical study of consecutive progressive keratoconic eyes that underwent either accelerated CXL (9 mW/cm 2 ultraviolet A (UVA) light irradiance for 10 min) or conventional CXL (3 mW/cm 2 ...

Financial strain and food insecurity are the strongest drivers of accelerated heart aging, Mayo Clinic researchers reported ...

The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?